A quiet transformation is unfolding across the cannabis industry. Companies that once focused on dispensaries and lifestyle brands are increasingly positioning themselves for a pharmaceutical future.
The shift accelerated after President Donald Trump signed a December 2025 executive order aimed at expanding medical marijuana and cannabidiol research while directing federal agencies to move forward with the marijuana rescheduling process.
The order did not immediately change federal drug classification. However, it signaled growing momentum toward a potential new framework for cannabinoid medicine.
That signal alone has already begun reshaping strategy across the cannabis sector.
Schedule III Has Not Happened Yet — But Companies Are Preparing
Marijuana has not officially moved to Schedule III under the Controlled Substances Act. The federal rulemaking process remains ongoing.
Trump’s executive order instructed the Attorney General to expedite the federal review related to rescheduling marijuana from Schedule I to Schedule III.
That distinction matters.
Rescheduling requires a formal regulatory process involving scientific review, rulemaking procedures, and public comment periods before becoming law.
Still, the order represents one of the clearest federal signals yet that cannabis research and medical development could expand significantly.
Because of that possibility, cannabis companies are studying how federally regulated medicines move through the healthcare system.
Many operators are now preparing for a future where cannabinoid therapies could operate within pharmaceutical frameworks.
The Federal Process Could Still Take Years
Even if regulators ultimately approve rescheduling, the shift would not happen overnight.
Federal drug scheduling changes involve multiple agencies and procedural steps.
Regulators must review scientific evidence, publish proposed rules, collect public comments, and finalize regulatory decisions.
Historically, federal drug policy changes have taken years to implement.
Because of that timeline, cannabis executives are watching the process closely while preparing for several possible outcomes.
In the meantime, the industry is beginning to align itself with a more medical and research-focused future.
Aurora Cannabis Goes All-In on Medical Markets
Some companies are already restructuring around that future.
Executives from Aurora Cannabis recently announced the company is now focusing solely on medical cannabis markets globally.
Speaking at the TD Cowen Healthcare Conference, Aurora leadership explained the company is exiting adult-use markets in order to concentrate on regulated medical systems.
The strategy targets countries with physician-driven cannabis programs, including Germany, Australia, and Poland.
Aurora’s financials show why the shift makes sense.
Medical cannabis already accounts for the vast majority of the company’s revenue and nearly all of its gross profit.
Those regulated medical markets also resemble pharmaceutical systems more closely than recreational cannabis markets.
Tilray Expands Its Medical Division in the U.S.
Another major operator moving in that direction is Tilray Brands.
The company recently announced the launch of Tilray Medical USA, a new division designed to expand medical cannabis and research initiatives in the United States.
The move positions Tilray to participate in a potential federally regulated medical cannabis framework if rescheduling ultimately moves forward.
Together, these strategic decisions highlight a broader trend.
Large cannabis companies are increasingly looking beyond retail dispensaries and toward medical markets.
Some Companies Started the FDA Journey Long Ago
While many operators are only now exploring medical development, some companies began pursuing that pathway years earlier.
One example is MMJ International Holdings.
Instead of focusing on dispensary markets, the company spent years working through the regulatory pathway required to develop cannabinoid-based medicines through the U.S. Food and Drug Administration.
That pathway requires strict manufacturing controls, standardized formulations, and controlled clinical trials.
MMJ’s research focuses on cannabinoid soft-gel capsules targeting neurological diseases including Huntington’s disease and multiple sclerosis.
The company’s Huntington’s disease program received Orphan Drug Designation from the FDA, recognizing the significant unmet medical need associated with the condition.
Why Most Cannabis Companies Avoided the FDA Path
For much of the industry’s history, cannabis companies avoided the pharmaceutical pathway entirely.
The reason was simple.
Drug development is extremely difficult.
Pharmaceutical treatments must undergo years of scientific validation before reaching patients.
Botanical medicines like cannabis introduce additional complexity.
Cannabis plants contain hundreds of compounds that interact with each other in complex ways.
Regulators require researchers to understand those compounds in detail before human trials can begin.
Developers must also standardize plant genetics, cultivation conditions, and extraction methods.
Those requirements demand deep scientific infrastructure.
The Real Barrier in Pharmaceutical Cannabis: Time
Even the most well-funded companies cannot accelerate pharmaceutical development overnight.
Before clinical trials begin, researchers must complete botanical characterization and manufacturing validation.
Developers must then submit Investigational New Drug applications.
Clinical trials unfold in three phases.
Phase I evaluates safety. Phase II examines dosing and early effectiveness. Phase III confirms results across larger patient populations.
The full process often takes eight to twelve years.
Because of that timeline, companies already operating within the regulatory system may hold a significant advantage.
Industry Context: Cannabis May Be Entering a Medical Era
The cannabis industry spent the past decade building consumer brands, dispensaries, and lifestyle products.
Those markets will likely remain part of the industry.
However, many executives now believe the long-term opportunity could expand into regulated pharmaceutical medicine.
FDA-approved cannabinoid therapies could enter healthcare systems worldwide.
Prescription medicines operate under different economic rules than retail cannabis.
Doctors prescribe treatments. Insurance providers reimburse patients. Pharmaceutical companies distribute medicines through regulated supply chains.
If cannabinoid therapies eventually meet those standards, the cannabis economy could evolve dramatically.
Science Will Decide Cannabis Medicine’s Future
Ultimately, cannabis will not become mainstream medicine through policy debates alone.
It will require scientific evidence.
Controlled clinical trials must demonstrate safety, dosage reliability, and therapeutic effectiveness.
That evidence determines whether plant compounds become prescription therapies.
Some companies began that work years ago.
Others are only beginning to explore it.
As federal policy continues evolving, the cannabis industry may find itself entering a new era—one defined less by dispensaries and more by regulated medicine.
Black Cannabis Magazine is your go-to platform for cannabis culture, news, and lifestyle content with a focus on diversity and inclusion. For more information, visit www.blackcannabismagazine.com.
Copyright 2026 Black Cannabis Magazine. Distributed by Hazey Taughtme, LLC.
